Key points are not available for this paper at this time.
Abstract Introduction: Pediatric acute lymphoblastic leukemia (P-ALL) is globally most common pediatric cancer. Cytogenetics remains the independent predictor of its clinical outcomes despite technological and treatment advances in 21st century. Tthe Fusion oncogenes (FOs) caused by chromosomal abnormalities not only play a significant role in the development of pediatric B cell acute lymphoblastic leukemia (ALL) but also serve as basis of its prognostic stratification (favorable prognosis versus poor prognosis) as well as clinical protocol selection (3-drug protol for favorable prognosis group versus 4-5 drug protocol for poor prognostic group). The predominant fusion oncogenes (FOs) include BCR-ABL, MLL-AF4, ETV6-RUNX1, and TCF3-PBX1, all of which carry significant prognosis and treatment selection implications. Furthermore, the frequencies of FOs exhibit ethnic variances. P-ALL is Pakistan have historically poor outcome for which underlying genetic reasons are unexplored at national level. Therefore, we aimed to investigate frequency of FOs of prognostic significance in P-ALL, their treatment outcome and survival.Patients p = 0.03). TCF3-PBX1 (2.1 %) was linked to a worse outcome and an increased risk of relapse in the central nervous system (CNS). MLL-AF4 (18.1 %) was more prevalent in the 8- to 15-year age group (24/34; p = 0.001) and was associated with organomegaly, low platelet count, and poor survival. BCR-ABL (47.9 %) was associated with older age (7–15 years, 52/90), lower remission rates, shorter survival (43.73 ± 4.24 weeks), and a higher white blood cell count. BCR-ABL results were confirmed using interphase FISH. MLL-AF4 and BCR-ABL were found in 66% of B-ALL cases, which typically occurred in older children. Discussion, conclusions 2024 Sep 5-8; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Res 2024;84(17 Suppl):Abstract nr B039.
AlMukhaylid et al. (Thu,) studied this question.